Literature DB >> 10999843

The prevalence and characteristics of colorectal neoplasia in acromegaly.

A G Renehan1, P Bhaskar, J E Painter, S T O'Dwyer, N Haboubi, J Varma, S G Ball, S M Shalet.   

Abstract

An increased prevalence of colorectal neoplasia has been reported in acromegalic patients, and recommendations have been made for early colonoscopic screening and regular surveillance. This assumption, however, is frequently drawn from studies using selected control populations. To clarify colonoscopic management in these patients, we undertook a 2-center prospective screening colonoscopy study in 122 acromegalics (age range, 25-82 yr). In the absence of ideal age-matched controls, we calculated prevalence rates of occult adenocarcinomas and adenomas in the general population using cumulative data in the published literature from 8 autopsy studies (model 1, n = 3,559) and 4 screening colonoscopy studies (model 2, n= 810), applying linear regression models. Of the 115 patients with complete examinations, adenocarcinomas were discovered in 3 (2.6%), and at least 1 adenoma was found in 11, giving an overall prevalence of neoplasia of 12% (14 of 115). Prevalence rates for age bands 30-40, 40-49, 50-59, 60-69, and 70+ yr were 0%, 8%, 12%, 20%, and 21%, respectively. Compared with the 2 control models, the prevalence of occult colorectal cancer was not significantly increased (acromegalics vs. models 1 and 2, 2.6% vs. 2.3% and 0.9%), nor was there an increase in the prevalence of adenomas in any age band. Pathological characteristics showed some differences, in that adenomas in acromegalics tended to be right sided (68% vs. 57% and 56%), larger (for > or =10 mm, 27% vs. 13% and 9%), and of advanced histology (for tubulovillous, 27% vs. 4% and 22%). No associations were found between the presence of colonic neoplasia and the duration of disease, total GH exposure, cure status, and serum insulin-like growth factor I. This study has failed to demonstrate an increased prevalence of neoplasia in acromegalic patients compared with the expected prevalence in the general population and questions the need for an aggressive colonoscopic screening policy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999843     DOI: 10.1210/jcem.85.9.6775

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

Review 3.  Role of insulin-like growth factor-1R system in colorectal carcinogenesis.

Authors:  Erin A Donovan; Shivaani Kummar
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-31       Impact factor: 6.312

Review 4.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

5.  MTHFR C677T polymorphism, folate status and colon cancer risk in acromegalic patients.

Authors:  Maria Luisa Torre; Giuseppina T Russo; Marta Ragonese; Annalisa Giandalia; Ernesto De Menis; Giorgio Arnaldi; Angela Alibrandi; Carmelo Buda; Giovanni Romanello; Elisabetta L Romeo; Domenico Cucinotta; Francesco Trimarchi; Salvatore Cannavo
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

6.  Serum factors associated with precancerous colonic lesions in acromegaly.

Authors:  M Lombardi; I Scattina; C Sardella; C Urbani; E Marciano; S Signori; L Ruocco; G Pellegrini; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2013-01-14       Impact factor: 4.256

7.  Colorectal neoplasm and acromegaly.

Authors:  Anil Bhansali; Pinaki Dutta; Mohammad Hayat Bhat; S K Sinha; R Kochar; K Vaiphi
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

8.  Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.

Authors:  Theodoros Rokkas; Dimitrios Pistiolas; Panos Sechopoulos; Georgios Margantinis; Georgios Koukoulis
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 9.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 10.  Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Authors:  Kevin C J Yuen; Anthony P Heaney; Vera Popovic
Journal:  Endocrine       Date:  2016-01-05       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.